Background Hyperimmune immunoglobulin (hIVIG) contains polyclonal antibodies, which
can be prepared from large amounts of pooled convalescent plasma or prepared from animal …

Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are being investigated as potential therapies …

Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as a potential therapy for …

Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Background The effectiveness of platelet transfusions to prevent bleeding in patients with
hematologic cancers remains unclear. This trial assessed whether a policy of not giving …

Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential
treatment of COVID-19. However, meta-analysis data and recommendations are limited. …

Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …

Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only for a …

Background Public concerns regarding the safety of blood have prompted reconsideration
of the use of allogeneic blood (blood from an unrelated donor) transfusion and a range of …

Background Despite modern antimicrobials and supportive therapy bacterial and fungal
infections are still major complications in people with prolonged disease‐related or treatment‐…